TOMO HDA와 Radixact 치료 계획 간 Transfer에 대한 유용성 평가 : Planning Study

Usability Assessment of Plan Transfer between TOMO HAD and Radixact : Planning Study

  • 안예찬 (삼성서울병원 방사선종양학과) ;
  • 김종식 (삼성서울병원 방사선종양학과) ;
  • 권동열 (삼성서울병원 방사선종양학과) ;
  • 김진만 (삼성서울병원 방사선종양학과) ;
  • 최병기 (삼성서울병원 방사선종양학과)
  • An, Ye Chan (Department of Radiation Oncology, Samsung Medical Center) ;
  • Kim, Jong Sik (Department of Radiation Oncology, Samsung Medical Center) ;
  • Kwon, Dong Yeol (Department of Radiation Oncology, Samsung Medical Center) ;
  • Kim, Jin Man (Department of Radiation Oncology, Samsung Medical Center) ;
  • Choi, Byeong Ki (Department of Radiation Oncology, Samsung Medical Center)
  • 발행 : 2018.12.29

초록

목 적 : iDMS(Integrated Database Management System, 통합 데이터베이스 관리 시스템) 내 TOMOTHERAPY 치료 계획을 ACCURAY $Precision^{TM}$ 1.1.1.1을 이용하여 본원의 TOMO HDA와 Radixact 장비 간 Transfer하였고 선량학적 차이를 분석하였으며, 이를 통해 치료 계획 Transfer의 유용성을 평가하였다. 대상 및 방법 : 두경부암 두 부위와 전립선암 두 부위의 치료를 가정하여 4개의 서로 다른 치료 계획을 세웠다. 각 치료 계획은 95 % 처방선량(Prescription dose)이 표적 체적의 99 % 이상 조사되도록 설계하였고, 정상장기 선량은 SMC tolerance dose protocol을 기준으로 하였다. 수립된 치료 계획은 각 장비로 Transfer 시켰으며 Transfer된 치료 계획의 DVH(Dose Volume Histogram) 분석을 통해 선량학적 차이를 비교 평가하였다. 결 과 : Transfer된 치료 계획에서 CTV 및 GTV의 Mean Dose는 증가 및 감소하였으나 유의할 만한 차이는 보이지 않았다. CTV 및 GTV 처방 선량의 Target Coverage는 HDA에서 Radixact로 Trasnfer 시 전부 감소하였으며, CTV에 대한 CI 및 HI 변화도 0.1 이내였다. Normal Organ Dose는 두 치료 계획 모두 HDA에서 Radixact로 Transfer 시 대부분의 항목에서 선량이 증가하였다. 결 론 : 본 실험의 결과에 따르면 Radixact에서 HDA 장비로 치료 계획 Transfer 시 Target Coverage는 기준 이상이었으며 Normal Organ Dose 또한 대부분 같거나 감소하였다. HDA에서 Radixact로 치료 계획 Transfer 시 Target의 Coverage는 감소하는 경향을 보였고, Normal Organ Dose는 Optic Chiasm($D_{max}$ 1.38 Gy 증가), Bladder($D_{max}$ 3.07 Gy 증가), Penile Bulb($D_{max}$ 1.14 Gy 증가) 등 부작용(side effects)을 일으킬 수 있는 장기에서 선량이 증가였다. 이에 따라 치료 계획 Transfer 시 선량 변화에 주의해야 하며 장비 점검으로 인한 일회성 Transfer는 효율적인 방사선 치료를 위해 유용할 것이나, Transfer된 치료 계획으로 치료가 수회간 이어질 경우 치료 계획을 다시 세워 진행해야 할 것으로 사료된다.

Purpose : To evaluate the usability of plan transfer between TOMO HD and Radixact, we compared the differences of dose in transferred plans by evaluating the dose of normal organ and target. TOMO HDA and Radixact. The completed plans were transferred each other and we compared the differences of dose by evaluating the DVH of each plans. Materials and Methods : We planned 4 different plans assuming the treatment of 2 cases in Head and Neck Cancer and 2 cases Prostate cancer. Each plan was designed so that 95 % of the prescription dose was irradiated over 99 % of the target volume, and the normal organ constraints dose was based on the SMC tolerance dose protocol. Each plan was transferred to each equipment and DVH(dose volume histogram) analysis of the transferred plans was compared and evaluated. Results : The Mean dose of CTV and GTV was increased and decreased in the transferred plans, but there was no significant differences. The target coverage of CTV and GTV was decreased in all cases of transferred plans from TOMO HAD to Radixact, and the change of CI and HI in CTV was within 0.1. Normal organ dose was increased in most cases when transferring from HAD to Radixact in both treatment plans. Conclusion : According to the results of this experiment, the target coverage was above the standard and the normal organ dose was almost same or decreased when transferring the plans from Radixact to HDA equipment. However the target coverage was reduced when transferring the plans from HDA to Radixact and there was an increase in dose in normal organs that could cause sever side effects such as Optic Chiasm ($D_{max}$1.38 Gy), Bladder ($D_{max}$3.07 Gy), Penile Bulb ($D_{max}$1.14 Gy). Therefore, it is necessary to pay attention to the dose change when transferring the plan and one-time transfer due to equipment inspection will be useful for efficient radiation therapy, but if the transferred treatment plans continue for several consecutive days, the treatment plan should be resumed.

키워드

참고문헌

  1. Adelstein DJ, Li Y, Adams GL, Wanger H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA: An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer, The Journal OF CLINICAL ONCOLOGY, V.21, No. 1, 2003, pp. 92-98 https://doi.org/10.1200/JCO.2003.01.008
  2. John F. Fowler: The linear-quadratic formula a nd progress in fractionated radiotherapy, The British Institute of Radiology, Vo.62, 1989, Issue 740
  3. Xin Zhang, Jose Penagaricano, Ganesh Narayanasamy, Peter Corry, TianXiao Liu, Maraboyina Sanjay, Nava Paudel, Steven Morrill: Helical Tomotherapy to LINAC plan conversion utilizing Raystation Fallback planning, Journal of Applied Clinical Medical Physics, V.18, Issue 1, 2017, pp 178-185 https://doi.org/10.1002/acm2.12147
  4. WEI WANG, HUI YANG, LING GUO, HONGYU SU, SHIHUI WEI, XIULAN ZAHNG: Radiation-induced optic neuropathy following external beam radiation therapy for nasopharyngeal carcinoma: A retrospective case-control study, Molecular and Clinical Oncology, V.4, No.5, 2016, pp. 868-872 https://doi.org/10.3892/mco.2016.787
  5. Mack Roach. lll, Jiho Nam, Giovanna Gagliardi, Issam El Naqa, Joseph O. Deasy, Lawrence B. Marks: Radiation Dose-Volume Effects and the Penile Bulb, V.76, Issue 3, 2010, pp. 130-134 https://doi.org/10.1016/j.ijrobp.2009.04.094
  6. Daniel Liberman, Brian Mehus, Sean P. Elliott: Urinary adverse effects of pelvic radiotherapy, Translational Andrology and Urology, V.3, No. 2, 2014